Raymond James initiated coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target Based on “strong results” from Part A of the Phase 1/2 REVEAL trial and “constructive” feedback from FDA, the firm views Taysha as well-positioned for success in its pivotal trial for patients with Rett syndrome, the analyst tells investors. There are currently no approved therapies addressing the root genetic cause of Rett syndrome, which the firm sees giving Taysha “a clear path to success,” the analyst added.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Strategic Advantage and Positive Outlook: Taysha Gene Therapies Maintains Buy Rating
- Taysha Regains Full Rights to TSHA-102 Program
- Taysha Gene Therapies regains full rights to TSHA-102 program
- Taysha Gene Therapies price target raised to $9 from $8 at BofA
- Taysha Gene Therapies Presents Promising TSHA-102 Data